Budoprutug Biosimilar - Research Grade

Human

CD19ï؟½

5mg/ml

IgG1 - kappa

CHO Cells

https://www.imgt.org/mAb-DB/

ICH3002

P15391;P15391;P25918;P51677

Blue ice

CD19 is a B-cell-lineage co-receptor that amplifies B-cell receptor signaling and is a foundational target across lymphoma, leukemia and autoimmunity research. This antibody is an unconjugated, non-therapeutic analog of budoprutug, a human IgG1-kappa recombinant monoclonal for research use only. It is delivered in a low-endotoxin, in vivo-suitable formulation and produced in scalable milligram-to-gram quantities to support heavy-usage, high-throughput laboratories. It is suited to functional assays, B-cell depletion and ADCC studies, in vitro screening, CAR-target reference work and preclinical models investigating CD19 biology. The in vivo-suitable, low-endotoxin preparation is produced at milligram-to-gram scale to support sustained, high-throughput research programs.

RB4v1.2 ;B lymphocyte surface antigen B4, Leu-12

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

3-4 weeks